Abstract
In this presentation I describe the development of genomic profiling approaches for application for population based studies. The advent and application of large scale genomic methods raises major issues and opportunities for individuals. My focus in this talk is towards describing specific examples to describe benefits and pitfalls in genomic medicine and disease prevention. Variation in several variants are already being used to understand disease development. A first issue in application relates to the describing the population of study. Genomic analysis provides a very detailed evaluation of population membership, and this information is relevant to risk profiling but its application is problematic for selected groups according to their beliefs about group membership and historical origins. Within some populations, genetic profiling has had a very significant effect on disease managment. For example carbamazepine use can lead to Stevens-Johnson syndrome which confers a lethal side effects in some individuals according their HLA genotypes. Population-wide assessment was implemented in Taiwan leading to a near eradication of this disease. With a very limited number of genotypes some phenotypes such as eye and skin color can be deduced very effectively. Genetic analysis of the alpha 5 nicotinic receptor shows a very dramatic correlation with ability to quit smoking. Finally more complex sets of genotypes are useful for predicting risk for some common cancers such as prostate and breast cancer. These collections of genotypes are useful for designing research studies to identify high risk subjects and will be increasingly useful for organizing screening.
Citation Format: Christopher I. Amos. How will genomic information be useful to limit cancer risk behaviors? [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr PL04-04.
RSS Feeds